And, as I just wrote below, the full FDA Commission is in no manner bound by this Advisory Committee vote -- but it certainly stretches the odds on a new label in Merck's favor, any time soon -- as a result of IMPROVE-IT data. Having said that, I don't expect much of a dip on the NYSE, come tomorrow -- as not much new revenue would have been expected by Wall Street -- even with a "yes" vote today.
And so -- I have only more questions -- none of which will be answered until the full Commission votes next month.
So, I'll leave you with Larry's fine commentary -- on this busy, and quite strange, day in the FDA kingdom:
. . . .12/14/2015 15:36 -- Boy the whole ezetimibe saga is amazing. Someone should write a book about it. . . .
That, my friends is a capital suggestion!
No comments:
Post a Comment